# Evaluate the Safety and Clinical Activity of HH2853

> **NCT04390737** · PHASE1,PHASE2 · RECRUITING · sponsor: **Haihe Biopharma Co., Ltd.** · enrollment: 254 (estimated)

## Conditions studied

- FL Lymphoma
- Epithelioid Sarcoma
- Peripheral T Cell Lymphoma
- Advanced Solid Tumor

## Interventions

- **DRUG:** HH2853 Tablets

## Key facts

- **NCT ID:** NCT04390737
- **Lead sponsor:** Haihe Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-09-08
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 254 (ESTIMATED)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04390737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04390737, "Evaluate the Safety and Clinical Activity of HH2853". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04390737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*